Sanofi (SNYNF) has halted its venglustat clinical trial for the treatment of polycystic kidney disease as a Phase 2/3 study of the treatment …
Sanofi (SNYNF) announced that together with GlaxoSmithKline, it has begun enrolment in their Phase 3 clinical study to examine the safety, efficacy, and immunogenicity of their …
French drugmaker Sanofi and its US partner Translate Bio will kick off human Phase 1/2 clinical trials for MRT5500, its messenger RNA-based vaccine …
Sanofi’s CEO, Paul Hudson, said that the mRNA-based (messenger Ribonucleic acid) COVID-19 vaccine developed by the pharma giant and Translate Bio will not …
Sanofi has inked an agreement to help with the production and supply of 125 million doses of Pfizer-BioNTech’s COVID-19 vaccine in Europe. According …
French drugmaker Sanofi has made an offer to snap up biotech company Kiadis for an aggregate adjusted equity value of €308 million ($358.5 …
Sanofi (SNYNF) has entered into an agreement with Merck to conduct a Phase 2 clinical trial to evaluate the safety, pharmacokinetics, and preliminary …
Sanofi (SNYNF) and GlaxoSmithKline (GSK) intend to make available 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine, if approved by regulatory …
Sanofi (SNYNF) and Regeneron have announced that a pivotal Phase 3 trial of Dupixent (dupilumab) met its primary and all key secondary endpoints in children …
Regeneron Pharmaceuticals (REGN) and Sanofi have announced new results from a Dupixent (dupilumab) Phase 3 open-label extension trial that showed the safety and efficacy …
